Join our daily newsletter At The Bell to receive exclusive market insights
- Lifespot Health (LSH) has appointed Matthew Golden as CEO effective immediately
- Matthew is a commercial healthcare professional with almost 20 years experience in the pharmaceutical industry both in Australia and overseas
- He has worked with the likes of Medical Developments International where he drove the sales of the ‘Green Whistle’ used in pain relief
- At Lifespot, Matthew will review the company’s telehealth and medical cannabis inhaler strategies, and define the timing of its Medihale clinical trial
- Additionally, Rodney Harrington and Frank Cannavo will resume their respective roles of Non-Executive Chairman and Non-Executive Director
- Lifespot is up 17.7 per cent on the back of this news with shares trading for six cents each
Lifespot Health (LSH) has appointed Matthew Golden as CEO effective immediately.
Matthew is a commercial healthcare professional with almost 20 years experience in the pharmaceutical industry both in Australia and overseas.
He has a Masters of Marketing and a Bachelor of Science, both from Monash University in Melbourne.
He primarily worked at Pfizer Pharmaceuticals and Medical Developments International where he drove the sales of pain management products such as Penthrox which is known as the ‘Green Whistle’ for pain relief.
At Lifespot, Matthew will review the company’s telehealth and medical cannabis inhaler strategies, and define the timing of its Medihale clinical trial.
Additionally, Rodney Harrington and Frank Cannavo will resume their respective roles of Non-Executive Chairman and Non-Executive Director.
Lifespot is up 17.7 per cent on the back of this news with shares trading for six cents each at 3:24 pm AEDT.
